Literature DB >> 9678761

Deletion of the IgH intronic enhancer and associated matrix-attachment regions decreases, but does not abolish, class switching at the mu locus.

A Bottaro1, F Young, J Chen, M Serwe, F Sablitzky, F W Alt.   

Abstract

The IgH locus intronic enhancer (Emu), located in the intron between the J(H) segments and the Cmu gene, and flanked by two matrix attachment regions (MAR), has been shown to be a major regulator of IgH gene transcription and VDJ recombination. To define the potential role of Emu plus MAR in class switch recombination (CSR), we generated IgG-expressing hybridomas from B cells heterozygous for mutations that delete all of these elements or replace them with a neo(r) gene and analyzed the switch status of the mutated IgH loci. Emu/MAR-deleted IgH loci displayed a highly significant, although not complete, decrease in CSR when compared to unmutated loci in normal hybridomas. Surprisingly, mutant loci with a pgk promoter-driven neo(r) gene replacing the Emu/MAR showed relatively normal switch frequency. These findings indicate that the Emu/MAR region plays a significant, but not necessary role in facilitating class switching at the mu locus. Potential mechanisms for these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9678761     DOI: 10.1093/intimm/10.6.799

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  23 in total

1.  Transcriptional activation by LR1 at the Emu enhancer and switch region sites.

Authors:  L A Hanakahi; N Maizels
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

2.  Elucidation of IgH intronic enhancer functions via germ-line deletion.

Authors:  Thomas Perlot; Frederick W Alt; Craig H Bassing; Heikyung Suh; Eric Pinaud
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

3.  Requirement for enhancer specificity in immunoglobulin heavy chain locus regulation.

Authors:  Igor I Kuzin; Ludmila Bagaeva; Faith M Young; Andrea Bottaro
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

4.  YY1 controls Eμ-3'RR DNA loop formation and immunoglobulin heavy chain class switch recombination.

Authors:  Parul Mehra; Tatiana Gerasimova; Arindam Basu; Vibha Jha; Anupam Banerjee; Vishal Sindhava; Falon Gray; Corbett T Berry; Ranjan Sen; Michael L Atchison
Journal:  Blood Adv       Date:  2016-11-29

Review 5.  A transcriptional serenAID: the role of noncoding RNAs in class switch recombination.

Authors:  William T Yewdell; Jayanta Chaudhuri
Journal:  Int Immunol       Date:  2017-04-01       Impact factor: 4.823

6.  RPA accumulation during class switch recombination represents 5'-3' DNA-end resection during the S-G2/M phase of the cell cycle.

Authors:  Arito Yamane; Davide F Robbiani; Wolfgang Resch; Anne Bothmer; Hirotaka Nakahashi; Thiago Oliveira; Philipp C Rommel; Eric J Brown; Andre Nussenzweig; Michel C Nussenzweig; Rafael Casellas
Journal:  Cell Rep       Date:  2013-01-03       Impact factor: 9.423

7.  Recombination and transcription of the endogenous Ig heavy chain locus is effected by the Ig heavy chain intronic enhancer core region in the absence of the matrix attachment regions.

Authors:  E Sakai; A Bottaro; L Davidson; B P Sleckman; F W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Internal IgH class switch region deletions are position-independent and enhanced by AID expression.

Authors:  Darryll D Dudley; John P Manis; Ali A Zarrin; Lianne Kaylor; Ming Tian; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-11       Impact factor: 11.205

Review 9.  Cis-regulatory elements and epigenetic changes control genomic rearrangements of the IgH locus.

Authors:  Thomas Perlot; Frederick W Alt
Journal:  Adv Immunol       Date:  2008       Impact factor: 3.543

10.  Switch recombination and somatic hypermutation are controlled by the heavy chain 3' enhancer region.

Authors:  Wesley A Dunnick; John T Collins; Jian Shi; Gerwin Westfield; Clinton Fontaine; Paul Hakimpour; F Nina Papavasiliou
Journal:  J Exp Med       Date:  2009-11-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.